Related Experiment Video

Updated: Jul 15, 2026

An Orthotopic Murine Model of Human Prostate Cancer Metastasis
06:48

An Orthotopic Murine Model of Human Prostate Cancer Metastasis

Published on: September 18, 2013

Endoglin inhibits prostate cancer motility via activation of the ALK2-Smad1 pathway

C S Craft1, D Romero, C P H Vary

  • 1Division of Hematology/Oncology, Department of Medicine, Northwestern University Medical School, Northwestern University and the Robert H Lurie Cancer Center of Northwestern University, Chicago, IL, USA.

Oncogene
|May 15, 2007
PubMed

Insights

Endoglin suppresses prostate cancer cell motility by activating the ALK2-Smad1 pathway. This mechanism, involving specific receptor-kinase interactions, offers new insights into prostate cancer progression and potential therapeutic targets.

Area of Science:

  • Molecular Biology
  • Cancer Research
  • Cell Signaling

Background:

  • Endoglin, a TGFbeta superfamily receptor, is known to suppress prostate cancer (PCa) cell motility.
  • Loss of endoglin expression correlates with PCa progression, but its inhibitory mechanism remains unclear.

Purpose of the Study:

  • To elucidate the molecular mechanism by which endoglin inhibits PCa cell motility.
  • To investigate the role of Smad proteins and specific Type I activin receptor-like kinases (ALKs) in endoglin's function.

Main Methods:

  • Assessed TGFbeta-mediated cell motility and TGFbeta binding.
  • Measured Smad-specific phosphorylation and Smad-responsive promoter activity.
  • Utilized siRNA knockdown of Smad1 and ALK2 (and TGFbetaRI/ALK5), and employed constitutively active ALK2.

Main Results:

  • Endoglin constitutively activates Smad1, with minimal effect on Smad3.
  • Smad1 knockdown increased PCa cell motility and abolished endoglin's inhibitory effects.
  • Knockdown of ALK2, but not ALK5, abrogated endoglin's motility-reducing effects.
  • Constitutively active ALK2 restored low motility in endoglin-deficient cells.

Conclusions:

  • Endoglin decreases PCa cell motility via the ALK2-Smad1 signaling pathway.
  • This study reveals a novel mechanism for endoglin's tumor-suppressive function in prostate cancer.
  • Findings highlight the ALK2-Smad1 axis as a potential therapeutic target for prostate cancer treatment.

More Related Videos

Studying TGF-β Signaling and TGF-β-induced Epithelial-to-mesenchymal Transition in Breast Cancer and Normal Cells06:54

Studying TGF-β Signaling and TGF-β-induced Epithelial-to-mesenchymal Transition in Breast Cancer and Normal Cells

Published on: October 27, 2020

Murine Prostate Micro-dissection and Surgical Castration08:49

Murine Prostate Micro-dissection and Surgical Castration

Published on: May 11, 2016

Related Concept Videos

mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
TGF - β Signaling Pathway01:16

TGF - β Signaling Pathway

The TGF-β signaling pathway regulates cell growth, differentiation, adhesion, motility, and development. TGF-β ligands that induce TGF-β signaling are synthesized in their latent form. Several proteases or cell surface receptors such as integrins act upon the latent form, releasing the active ligand. There are three types of mammalian TGF-βs: (TGF-β1, TGF-β2, and TGF-β3) that bind as homodimers or heterodimers to TGF-β receptors. The TGF-β receptors are of three kinds RI, RII, and RIII. The RI...
Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
Cancer Cell Migration through Invadopodia01:35

Cancer Cell Migration through Invadopodia

Invadosome is a broad category of cell surface structures with proteolytic activity that  degrades the extracellular matrix (ECM). Invadosomes are present in normal cell types, including macrophages, endothelial cells, and neurons, as well as tumor cells. Although the macrophage podosomes and tumor cell invadopodia are classified as invadosomes, they have different structures, molecular pathways, and functions. Podosomes are short structures that last for a few minutes. However, invadopodia can...
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...